Kintara Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kintara Therapeutics, Inc., a biopharmaceutical firm, has focused its efforts on developing advanced treatments for solid tumor cancers. The company recently completed a definitive merger with TuHURA Biosciences, Inc., effective in October 2024, leading to Kintara becoming a wholly-owned subsidiary of TuHURA Biosciences. Following this transaction, the combined entity now operates under the name TuHURA Biosciences, Inc., trading on the Nasdaq Capital Market with the new ticker symbol 'HURA', and implemented a 1-for-35 reverse stock split. Previously, Kintara was developing two key therapeutic candidates. However, it has since suspended the development of VAL-083, a DNA-targeting agent, for glioblastoma multiforme, after preliminary clinical trial results did not demonstrate an improvement over existing standards of care. The company has now shifted its primary attention to its second program, REM-001. This proprietary, late-stage photodynamic therapy is specifically being evaluated for treating cutaneous metastatic breast cancer (CMBC), an area with significant unmet medical need. An open-label, 15-patient clinical study for REM-001 is underway to confirm the optimal dose and refine the study design in preparation for a Phase 3 trial, with substantial funding from a $2.0 million grant from the National Institutes of Health supporting these efforts. The newly formed TuHURA Biosciences will also advance its lead program, IFx-2.0, an immuno-oncology therapy aimed at overcoming resistance to cancer immunotherapy, with a Phase 3 trial anticipated to begin in the latter half of 2024. The company maintains its operational presence in San Diego, California.
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today?